Increased frequency and suppression by regulatory T cells in patients with acute myelogenous leukemia

Clinical Cancer Research

Volumn 15, Issue 10, 2009, Pages 3325-3332

  Szczepanski, Miroslaw J ^b   Szajnik, Marta ^b   Czystowska, Malgorzata ^b   Mandapathil, Magis ^b   Strauss, Laura ^b   Welsh, Ann ^a,b   Foon, Kenneth A ^a,b   Whiteside, Theresa L ^a,b   Boyiadzis, Michael ^a,b  

^a UNIVERSITY OF PITTSBURGH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; INTERLEUKIN 10; TRANSFORMING GROWTH FACTOR BETA1;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CD4+ CD25+ T LYMPHOCYTE; CELL CONTACT; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROL GROUP; CONTROLLED STUDY; FEMALE; HUMAN; INCUBATION TIME; MALE; PERIPHERAL CIRCULATION; PHENOTYPE; PRIORITY JOURNAL; PROSPECTIVE STUDY; REGULATORY T LYMPHOCYTE; REMISSION; TREATMENT OUTCOME;

ACUTE DISEASE; ADENOSINE TRIPHOSPHATE; ANTIGENS, CD4; CYTOKINES; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; INTERLEUKIN-2 RECEPTOR ALPHA SUBUNIT; LEUKEMIA, MYELOID; PROGNOSIS; T-LYMPHOCYTES, REGULATORY;

EID: 66149179122     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-08-3010     Document Type: Article

References (33)

1. Ferrone S, Whiteside TL. Tumor microenvironment and immune escape. Surg Oncol Clin N Am 2007;16:755-74, viii. (Pubitemid 350101281)
2. Whiteside TL. Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol 2006;16:3-15. (Pubitemid 43139705)
3. + regulatory T cells for immunologic self-tolerance and negative control of immune responses. Annu Rev Immunol 2004;22:531-562
4. Hori S, Nomura T, Sakaguchi S. Control of regulatory T cell development by the transcription factor Foxp3. Science 2003;299:1057-1061 (Pubitemid 36222930)
5. + regulatory T cells in immunological tolerance to self and non-self. Nat Immunol 2005;6:345-352
6. Hinz S, Pagerols-Raluy L, Oberg HH, et al. Foxp3 expression in pancreatic carcinoma cells as a novel mechanism of immune evasion in cancer. Cancer Res 2007;67:8344-8350 (Pubitemid 47395173)
7. Yamamoto M, Tsuji-Takayama K, Suzuki M, et al. Comprehensive analysis of FOXP3 mRNA expression in leukemia and transformed cell lines. Leuk Res 2008;32:651-658
8. Ziegler SF. Foxp3: not just for regulatory T cells anymore. Eur J Immunol 2007;37:21-23 (Pubitemid 46128782)
9. Rudensky AY, Gavin M, Zheng Y. FOXP3 and NFAT: partners in tolerance. Cell 2006;126:253-256 (Pubitemid 44092973)
10. Wu Y, Borde M, Heissmeyer V, et al. FOXP3 controls regulatory T cell function through cooperation with NFAT. Cell 2006;126:375-387 (Pubitemid 44092960)
11. Strauss L, Bergmann C, Gooding W, Johnson JT, Whiteside TL. The frequency and suppressor function of CD4+CD25highFoxp3+ T cells in the circulation of patients with squamous cell carcinoma of the head and neck. Clin Cancer Res 2007;13:6301-6311 (Pubitemid 47094395)
12. + Treg clones obtained from peripheral blood of patients with cancer. Int J Cancer 2007;121:2473-2483
13. Zhu J, Paul WE. CD4 T cells: fates, functions, and faults. Blood 2008;112:1557-1569
14. Gattinoni L, Powell DJ, Jr., Rosenberg SA, Restifo NP. Adoptive immunotherapy for cancer: building on success. Nat Rev Immunol 2006;6:383-393
15. + T helper cells and hindered by naturally occurring T regulatory cells. J Immunol 2005;174:2591-2601
16. Onizuka S, Tawara I, Shimizu J, Sakaguchi S, Fujita T, Nakayama E. Tumor rejection by in vivo administration of anti-CD25 (interleukin-2 receptor α) monoclonal antibody. Cancer Res 1999;59:3128-3133 (Pubitemid 29316012)
17. + T cells: a common basis between tumor immunity and autoimmunity. J Immunol 1999;163:5211-5218
18. Beyer M, Schultze JL. Regulatory T cells in cancer. Blood 2006;108:804-811 (Pubitemid 44154611)
19. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat Rev Immunol 2006;6:295-307.
20. + Treg cells: hydrolysis of extracellular ATP and immune suppression. Blood 2007;110:1225-1232
21. Deaglio S, Dwyer KM, Gao W, et al. Adenosine generation catalyzed by CD39 and CD73 expressed on regulatory T cells mediates immune suppression. J Exp Med 2007;204:1257-1265 (Pubitemid 46919862)
22. Woo EY, Chu CS, Goletz TJ, et al. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res 2001;61:4766-4772 (Pubitemid 32691889)
23. Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med 2004;10:942-949 (Pubitemid 39273735)
24. Griffiths RW, Elkord E, Gilham DE, et al. Frequency of regulatory T cells in renal cell carcinoma patients and investigation of correlation with survival. Cancer Immunol Immunother 2007;56:1743-1753 (Pubitemid 47313079)
25. Fauriat C, Just-Landi S, Mallet F, et al. Deficient expression of NCR in NKcells from acute myeloid leukemia: evolution during leukemia treatment and impact of leukemia cells in NCR dull phenotype induction. Blood 2007;109:323-330 (Pubitemid 46053073)
26. Fauriat C, Moretta A, Olive D, Costello RT. Defective killing of dendritic cells by autologous natural killer cells from acute myeloid leukemia patients. Blood 2005;106:2186-2188 (Pubitemid 41291738)
27. + regulatory T cells cultured with rapamycin. J Immunol 2007;178:320-329
28. Slovak ML, Kopecky KJ, Cassileth PA, et al. Karyotypic analysis predicts outcome of preremission and postremission therapy in adult acute myeloid leukemia: a Southwest Oncology Group/Eastern Cooperative Oncology Group Study. Blood 2000;96:4075-4083
29. Wang X, Zheng J, Liu J, et al. Increased population of CD4(+)CD25(high), regulatory T cells with their higher apoptotic and proliferating status in peripheral blood of acute myeloid leukemia patients. Eur J Haematol 2005;75:468-476 (Pubitemid 41687780)
30. Shimizu J, Yamazaki S, Takahashi T, Ishida Y, Sakaguchi S. Stimulation of CD25(+)CD4(+) regulatory T cells through GITR breaks immunological self-tolerance. Nat Immunol 2002;3:135-142 (Pubitemid 34141443)
31. + T suppressor cell clones produce transforming growth factor β, but not interleukin 10, and are distinct fromtype 1 T regulatory cells. J Exp Med 2002;196:1335-1346
32. Leach DR, Krummel MF, Allison JP. Enhancement of antitumor immunity by CTLA-4 blockade. Science 1996;271:1734-1736 (Pubitemid 26102823)
33. Phan GQ, Yang JC, Sherry RM, et al. Cancer regression and autoimmunity induced by cytotoxic T lymphocyte-associated antigen 4 blockade in patients with metastatic melanoma. Proc Natl Acad Sci U S A 2003;100:8372-8377 (Pubitemid 36842552)